*For medical professionals for reference
Focus on important targets- damage.
Diabetes Nephrine (DKD) is a chronic kidney disease caused by diabetes. The clinical characteristics are increased continuous urine protein excretion. It is estimated that (EGFR) Developed, and eventually developed into end -end renal diseases.Kidney foot cells are considered to be developed in DKD, especially in the occurrence of proteinuria.At present, the research on the medical field for kidney foot cell damage and DKD management are in full swing.
Based on this, the medical community invited Professor Wang Yangang, Affiliated Hospital of Qingdao University to discuss the strategy of treating diabetes and nephropathy for the target target target target for foot cells.
Foot cell damage is an important "behind -the -scenes black hand" of DKD
Foot cells are highly differentiated cells attached to the glomerular base membrane.The last barrier of the membrane [1].Foot cell damage can lead to increased glomerular permeability, allowing protein and other media to enter the renaloma, leading to proteinuria and renal dysfunction, playing a key role in the occurrence and progress of DKD [2].The performance of its damage mainly includes several types of foot cell detachment, foot cell apoptosis, foot cell hypertrophy, foot cell epithelial intercostal transformation, and kick cell autophagy. [3].
In the mechanism, foot cell damage is mainly related to the functions of metabolic disorders, oxidation stress, inflammatory factors, and white phase.Studies have shown that high sugar can cause damage to mitochondrial function of kidney tissue cells such as foot cells and renal epithelial cells.Mitochondria that cannot be cleared in time is an important source of activated oxygen in the cell, causing oxidation stress, inducing apoptosis and inflammatory response, and accelerating the occurrence and progress of DKD.Because of this, Professor Wang Yangang commented on "kidney foot cell damage" as an important target for treating DKD.
Multi -target control, delay DKD progress
Based on foot cell damage plays in the pathogenesis of DKDWith a key role, in recent years, the medical field has been actively looking for effective response measures against kidney foot cell damage, and has also made certain progress, which has played a certain role in delaying the progress of DKD.
A large number of studies have shown that strengthening the development of blood sugar, blood pressure, and blood lipids for patients with DKD can effectively slow down the development process of diabetic microvascular complications.Therefore, clinically, drug treatment is given clinically for DKD foot cell damage, and renal damage is delayed through antihypertensive, sugar reduction, lipid -lowering, and treatment of proteinuria.In the field of traditional Chinese medicine, DKD is the category of "thirst and kidney deficiency". Through metabolic regulation, antioxidation, anti -inflammatory, anti -fibrosis, foot cell protection, etc.The effect of wetting turbidity, nourishing the spleen and kidney, to a certain extent help delay the development process of DKD, fight against inflammatory response, thereby improving the treatment effect.
Multi -means strong help DKD management
The conventional management methods of DKD mainly include lifestyle intervention, blood sugar, blood sugarThe control of factors such as blood pressure, blood lipids, and albuminuria, and comprehensive management measures, including health education to enable patients to have self -management capabilities.Drug therapy plays an important role in it, such as sodium-glucose collaborative transfer protein-2 inhibitors (SGLT-2i), high-glucose-like peptide-1 receptor agonist (GLP-1ra), etc.Studies have shown that it has the effect of repairing DKD foot cell damage [2]. While effectively reducing sugar, it can reduce EGFR, reduce albuminuria, etc., and protect the kidneys."It should be noted that before using SGLT-2i, evaluate the patients EGFR level. For those who cannot achieve the ideal control effect after application, or those who have SGLT-2i taboos, they can use GLP-1RA-type drugs [5]." Wang Yangang.Professor added.
The field of Chinese medicine has also made certain progress in recent years.If some studies have found that some single -flavored drugs and their extracts have the function of protecting mitochondrial autophagy, which has a certain auxiliary effect on alleviating DKD [1].In addition, in terms of combination of traditional Chinese and Western medicine, Professor Wang Yangang said that in response to the important target of DKD kidney foot cell damage, future potential needs to be played. Some drug research is underway, and future data is expected to be announced.
Summary
In general, the DKD pathogenesis is complicated, kidney foot cell damage and DKDDevelopment is closely related to one of the important targets for the treatment of DKD.At present, the treatment of DKDs drugs is mostly delayed renal damage through antihypertensive, sugar reduction, lipid -lowering, and treatment of proteinuria.The advantages of Chinese medicine due to less adverse reactions [6] can be used as auxiliary means to treat DKD kidney foot cell damage. The combination of the two provides patients with a more comprehensive treatment plan.
Expert Introduction
Wang Yangang Professor
I have studied in Johns Hopkins University in the United States for a yearSheffield Teaching Hospital Learn Neuropathy
Leading talents in Qilu Health in Shandong Province, Qingdao City Pulling Talent
Once served as the 7th and 8th members of the Diabetes Society of the Chinese Medical Association
Member of the Endocrine Branch of the Chinese Medical Association
Standing Committee Member of the Chinese Physician Association Endocrine Professional Committee
Deputy Chairman of the Endocrine Professional Committee of the Chinese and Western Medicine Society of Chinese and Western Medicine
The chairman of the Endocrine Branch of the Shandong Medical Association
Shandong Chinese and Western MedicineBased on the chairman of the Societys Endocrinology Professional Committee
Chairman of the Qingdao Endocrinology Society
Winning 9 national invention patents, undertaking the key special projects of the Ministry of Science and Technology, National Natural Fund, Shandong Provincial Fund, Natural Fund project, Major projects in Qingdao.He serves as editorial board of China Endocrine Magazine and Editorial Committee of China Diabetes Magazine.
References:
[1] Liu Danning, et al., Guangxi Medicine, 2021, 043 (008): 1008-1010.
[2] Kong Yingjie, et al.19): 2764-2768.
[3] zhang l, et al. J diabetes res. 2020; 2020: 7504798.= "35skha5v"> [4] Tang G, et al. Acta Pharm sin B. 2021; 11 (9): 2749-2767.
[5] Li Huiling, etc.Medical Engineering, 2023, 30 (8): 1175-1176.
[6] In the National Yong, et al.592.
"This article is only used to provide scientific information to medical professionals, not representing the platform position"
